Serum positivity to an antigen recognized by the monoclonal antibody (MAb) which will be administered is frequently being used as a predictive criterion for positive MAb tumor localization. In the present study, which is based on our previous data that clearly showed no correlation between quantitative levels of CEA in sera and in carcinoma tissues, we selected a population of 12 primary colorectal carcinoma patients which were serum CEA-negative. The main purpose was to assess the potential diagnostic use of Radioimmunoguided Surgery (RIGS) with an anti-CEA FO23C5 F(Ab')2 MAb and its clinical value in this series of patients. In all RIGS patients, the MAb localized to histologically confirmed tumor; this included 96% of primary tumor tissues, 29% of lymph nodes and one occult liver metastasis. Thus, serum CEA positivity should not be a criterion for the use of anti-CEA MAbs for the diagnosis of colon cancer, since the serum CEA level is not indicative of CEA expression in tumors.

Roselli, M., Guadagni, F., Buonomo, O.c., Belardi, A., Vittorini, V., Cavazzana, A., et al. (1992). Intraoperative radioimmunolocalization of an anti-CEA MAb F(Ab')2 (FO23C5) in CEA serum-negative colorectal cancer patients. ANTICANCER RESEARCH, 16(2), 883-889.

Intraoperative radioimmunolocalization of an anti-CEA MAb F(Ab')2 (FO23C5) in CEA serum-negative colorectal cancer patients

ROSELLI, MARIO;BUONOMO, ORESTE CLAUDIO;VITTORINI, VALERIO;SPAGNOLI, LUIGI GIUSTO;
1992-01-01

Abstract

Serum positivity to an antigen recognized by the monoclonal antibody (MAb) which will be administered is frequently being used as a predictive criterion for positive MAb tumor localization. In the present study, which is based on our previous data that clearly showed no correlation between quantitative levels of CEA in sera and in carcinoma tissues, we selected a population of 12 primary colorectal carcinoma patients which were serum CEA-negative. The main purpose was to assess the potential diagnostic use of Radioimmunoguided Surgery (RIGS) with an anti-CEA FO23C5 F(Ab')2 MAb and its clinical value in this series of patients. In all RIGS patients, the MAb localized to histologically confirmed tumor; this included 96% of primary tumor tissues, 29% of lymph nodes and one occult liver metastasis. Thus, serum CEA positivity should not be a criterion for the use of anti-CEA MAbs for the diagnosis of colon cancer, since the serum CEA level is not indicative of CEA expression in tumors.
1992
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/08 - ANATOMIA PATOLOGICA
English
Carcinoembryonic Antigen; Rectal Neoplasms; Humans; Aged; Antibodies, Monoclonal; Radioimmunodetection; Iodine Radioisotopes; Middle Aged; Intraoperative Period; Colonic Neoplasms; Tumor Markers, Biological; Female; Male
Roselli, M., Guadagni, F., Buonomo, O.c., Belardi, A., Vittorini, V., Cavazzana, A., et al. (1992). Intraoperative radioimmunolocalization of an anti-CEA MAb F(Ab')2 (FO23C5) in CEA serum-negative colorectal cancer patients. ANTICANCER RESEARCH, 16(2), 883-889.
Roselli, M; Guadagni, F; Buonomo, Oc; Belardi, A; Vittorini, V; Cavazzana, A; Spagnoli, Lg; Cipriani, C; Casciani, C
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/66814
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact